Evaluating antithrombotic activity of HY023016 on rat hypercoagulable model

Area of Science:

• Pharmacology
• Hematology
• Thrombosis Research

Background:

• Thrombus generation involves complex pathological processes that can exacerbate hypercoagulability.
• Understanding the impact of anticoagulants on hypercoagulable states is crucial for developing effective antithrombotic therapies.

Purpose of the Study:

• To evaluate the efficacy of HY023016, a novel dabigatran prodrug, and dabigatran etexilate in improving in vitro and in vivo hypercoagulable states.
• To compare the effects of HY023016 and dabigatran etexilate on platelet-leukocyte aggregation and thrombus formation.

Main Methods:

• Whole blood flow cytometry was used to assess platelet-leukocyte aggregation induced by thrombin and ADP in vitro.
• A rat hypercoagulable model was established via continuous intravenous thrombin infusion to evaluate drug efficacy in vivo.
• Antithrombotic activity was assessed by measuring thrombus formation in rats and extracorporeal circulation models.

Main Results:

• HY023016 dose-dependently inhibited thrombin- or ADP-induced platelet-leukocyte aggregation and related markers.
• Dabigatran etexilate did not inhibit ADP-induced platelet-leukocyte aggregation but reversed thrombin-induced hypercoagulability in rats.
• HY023016 exhibited comparable or superior antithrombotic activity to dabigatran etexilate in various models.

Conclusions:

• HY023016 effectively improves the hypercoagulable state of the circulatory system.
• HY023016 demonstrates significant potential as an antithrombotic agent with broad-spectrum efficacy.
• The novel dabigatran prodrug HY023016 offers a promising therapeutic option for managing hypercoagulable conditions.